The ACE gene D/I polymorphism as a modulator of severity of cystic fibrosis

BMC Pulmonary Medicine

Table 4 Association of the ACE gene D/I polymorphism, without CFTR genotype distribution and presence of B. cepacia (BC)

Group	Ace genotype	Presence	Absence	Total	X²	p	X²	p	OR (CI 5-95%)
Without taking CFTR mutation into account	I/I	8	64	72	8.654	0.013	0.468	0.498	0.699 (0.319 – 1.534)
	I/D	9	74	82			0.814	0.182	0.651 (0.304 – 1.394)
	D/D	8	16	24			8,653	0.003	4.509 (1.513 – 10.89)
No identified CFTR mutation	I/I	3	18	21	0.530	0.767	0.003	1.29	1.056 (0.188 - 5.925)
	I/D	2	16	18			0.204	1.00	0.656 (0.107 - 4.041)
	D/D	1	3	4			0.438	0.93	2.267 (0.196 - 26.27)
One CFTR mutation identified class I, II or III	I/I	2	20	22	5.539	0.063	1.248	0.466	0.383 (0.069 - 2.117)
	I/D	2	18	20			0.787	0.629	0.463 (0.084 - 2.562)
	D/D	4	5	9			6.834	0.027	7.6 (1.43 - 40.38)
Two CFTR mutation identified class I, II or III	I/I	3	26	29	0.511	0.774	0.084	1.07	0.8077 (0.193 - 3.387)
	I/D	5	40	45			0.039	1.10	0.875 (0.234 - 3.275)
	D/D	2	9	11			0.495	0.764	1.833 (0.335 - 10.02)

Values below 0.05 for p denote clinical correlation between variables. OR - odds ratio, CI- confidence interval, D - deleted allele, I - insertion allele. No identified mutation (44 patients) – patients without of identified mutation in classes I, II or III. One identified mutation (51 patients) – patient with one identified mutation in class I, II, or III. Two identified mutation (85 patients) – patient with two mutations in class I, II or III.

ISSN: 1471-2466